vs
Side-by-side financial comparison of Affinity Bancshares, Inc. (AFBI) and STRATA Skin Sciences, Inc. (SSKN). Click either name above to swap in a different company.
STRATA Skin Sciences, Inc. is the larger business by last-quarter revenue ($9.3M vs $8.6M, roughly 1.1× Affinity Bancshares, Inc.). Affinity Bancshares, Inc. runs the higher net margin — 24.9% vs 0.6%, a 24.3% gap on every dollar of revenue. On growth, Affinity Bancshares, Inc. posted the faster year-over-year revenue change (12.8% vs -3.0%). Affinity Bancshares, Inc. produced more free cash flow last quarter ($11.2M vs $-551.0K). Over the past eight quarters, STRATA Skin Sciences, Inc.'s revenue compounded faster (17.3% CAGR vs 8.1%).
Strata Skin Sciences is an American medical device company focused on the design, development and commercialization of non-invasive tools to provide additional information to dermatologists during melanoma skin examinations.
AFBI vs SSKN — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $8.6M | $9.3M |
| Net Profit | $2.1M | $58.0K |
| Gross Margin | — | 61.8% |
| Operating Margin | 35.9% | 5.3% |
| Net Margin | 24.9% | 0.6% |
| Revenue YoY | 12.8% | -3.0% |
| Net Profit YoY | 58.5% | 101.3% |
| EPS (diluted) | $0.34 | $0.14 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $8.6M | $9.3M | ||
| Q3 25 | $8.4M | $6.9M | ||
| Q2 25 | $8.3M | $7.7M | ||
| Q1 25 | $7.8M | $6.8M | ||
| Q4 24 | $7.6M | $9.6M | ||
| Q3 24 | $8.0M | $8.8M | ||
| Q2 24 | $8.3M | $8.4M | ||
| Q1 24 | $7.3M | $6.8M |
| Q4 25 | $2.1M | $58.0K | ||
| Q3 25 | $2.2M | $-1.6M | ||
| Q2 25 | $2.2M | $-2.6M | ||
| Q1 25 | $1.8M | $-2.1M | ||
| Q4 24 | $1.3M | $-4.6M | ||
| Q3 24 | $1.7M | $-2.1M | ||
| Q2 24 | $1.0M | $-91.0K | ||
| Q1 24 | $1.3M | $-3.4M |
| Q4 25 | — | 61.8% | ||
| Q3 25 | — | 60.4% | ||
| Q2 25 | — | 56.2% | ||
| Q1 25 | — | 53.5% | ||
| Q4 24 | — | 61.4% | ||
| Q3 24 | — | 60.1% | ||
| Q2 24 | — | 59.0% | ||
| Q1 24 | — | 45.6% |
| Q4 25 | 35.9% | 5.3% | ||
| Q3 25 | 34.9% | -16.9% | ||
| Q2 25 | 34.1% | -30.1% | ||
| Q1 25 | 30.8% | -25.0% | ||
| Q4 24 | 21.1% | -44.7% | ||
| Q3 24 | 28.5% | -18.2% | ||
| Q2 24 | 16.2% | -5.7% | ||
| Q1 24 | 24.0% | -42.7% |
| Q4 25 | 24.9% | 0.6% | ||
| Q3 25 | 26.5% | -23.4% | ||
| Q2 25 | 25.9% | -33.6% | ||
| Q1 25 | 23.4% | -31.2% | ||
| Q4 24 | 17.7% | -47.6% | ||
| Q3 24 | 21.7% | -23.6% | ||
| Q2 24 | 12.5% | -1.1% | ||
| Q1 24 | 18.2% | -49.8% |
| Q4 25 | $0.34 | $0.14 | ||
| Q3 25 | $0.34 | $-0.36 | ||
| Q2 25 | $0.33 | $-0.62 | ||
| Q1 25 | $0.28 | $-0.51 | ||
| Q4 24 | $0.21 | $-2.01 | ||
| Q3 24 | $0.26 | $-0.51 | ||
| Q2 24 | $0.16 | $-0.03 | ||
| Q1 24 | $0.20 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $53.9M | $7.9M |
| Total DebtLower is stronger | — | $15.3M |
| Stockholders' EquityBook value | $127.0M | $2.9M |
| Total Assets | $881.7M | $30.5M |
| Debt / EquityLower = less leverage | — | 5.28× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $53.9M | $7.9M | ||
| Q3 25 | $84.8M | $7.1M | ||
| Q2 25 | $89.7M | $6.0M | ||
| Q1 25 | $74.7M | $6.5M | ||
| Q4 24 | $41.4M | $7.3M | ||
| Q3 24 | $52.3M | $7.1M | ||
| Q2 24 | $50.4M | $5.5M | ||
| Q1 24 | $61.4M | $5.2M |
| Q4 25 | — | $15.3M | ||
| Q3 25 | — | $15.3M | ||
| Q2 25 | — | $15.0M | ||
| Q1 25 | — | $15.0M | ||
| Q4 24 | — | $15.0M | ||
| Q3 24 | — | $15.0M | ||
| Q2 24 | — | $15.0M | ||
| Q1 24 | — | $15.0M |
| Q4 25 | $127.0M | $2.9M | ||
| Q3 25 | $125.4M | $1.3M | ||
| Q2 25 | $124.1M | $532.0K | ||
| Q1 25 | $122.3M | $3.0M | ||
| Q4 24 | $129.1M | $5.0M | ||
| Q3 24 | $128.4M | $9.4M | ||
| Q2 24 | $125.1M | $9.5M | ||
| Q1 24 | $123.3M | $9.4M |
| Q4 25 | $881.7M | $30.5M | ||
| Q3 25 | $925.2M | $30.7M | ||
| Q2 25 | $933.8M | $29.5M | ||
| Q1 25 | $912.5M | $33.0M | ||
| Q4 24 | $866.8M | $34.9M | ||
| Q3 24 | $878.6M | $39.4M | ||
| Q2 24 | $873.6M | $38.8M | ||
| Q1 24 | $869.5M | $39.2M |
| Q4 25 | — | 5.28× | ||
| Q3 25 | — | 11.65× | ||
| Q2 25 | — | 28.20× | ||
| Q1 25 | — | 5.04× | ||
| Q4 24 | — | 3.02× | ||
| Q3 24 | — | 1.60× | ||
| Q2 24 | — | 1.58× | ||
| Q1 24 | — | 1.59× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $11.6M | $-239.0K |
| Free Cash FlowOCF − Capex | $11.2M | $-551.0K |
| FCF MarginFCF / Revenue | 130.9% | -5.9% |
| Capex IntensityCapex / Revenue | 4.9% | 3.4% |
| Cash ConversionOCF / Net Profit | 5.46× | -4.12× |
| TTM Free Cash FlowTrailing 4 quarters | $20.3M | $-4.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $11.6M | $-239.0K | ||
| Q3 25 | $3.7M | $-64.0K | ||
| Q2 25 | $3.8M | $-1.9M | ||
| Q1 25 | $1.9M | $-550.0K | ||
| Q4 24 | $6.8M | $703.0K | ||
| Q3 24 | $4.1M | $-302.0K | ||
| Q2 24 | $619.0K | $591.0K | ||
| Q1 24 | $1.2M | $-804.0K |
| Q4 25 | $11.2M | $-551.0K | ||
| Q3 25 | $3.6M | $-1.1M | ||
| Q2 25 | $3.7M | $-2.0M | ||
| Q1 25 | $1.8M | $-749.0K | ||
| Q4 24 | $6.4M | $199.0K | ||
| Q3 24 | $4.0M | $-364.0K | ||
| Q2 24 | $489.0K | $246.0K | ||
| Q1 24 | $1.1M | $-1.5M |
| Q4 25 | 130.9% | -5.9% | ||
| Q3 25 | 43.3% | -15.6% | ||
| Q2 25 | 44.0% | -26.1% | ||
| Q1 25 | 22.7% | -11.0% | ||
| Q4 24 | 83.9% | 2.1% | ||
| Q3 24 | 49.5% | -4.1% | ||
| Q2 24 | 5.9% | 2.9% | ||
| Q1 24 | 14.8% | -22.6% |
| Q4 25 | 4.9% | 3.4% | ||
| Q3 25 | 0.8% | 14.7% | ||
| Q2 25 | 1.4% | 0.8% | ||
| Q1 25 | 1.9% | 2.9% | ||
| Q4 24 | 5.6% | 5.3% | ||
| Q3 24 | 1.7% | 0.7% | ||
| Q2 24 | 1.6% | 4.1% | ||
| Q1 24 | 1.8% | 10.7% |
| Q4 25 | 5.46× | -4.12× | ||
| Q3 25 | 1.66× | — | ||
| Q2 25 | 1.75× | — | ||
| Q1 25 | 1.05× | — | ||
| Q4 24 | 5.05× | — | ||
| Q3 24 | 2.36× | — | ||
| Q2 24 | 0.60× | — | ||
| Q1 24 | 0.91× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AFBI
Segment breakdown not available.
SSKN
| Dermatology Recurring Procedures | $6.1M | 65% |
| Dermatology Procedures Equipment | $3.2M | 35% |
